GlassScriptPhysician profile
Sheryl List
NPI 1962020875
$4,029.18
in general payments reported to CMS, 2019-2025
22 companies · $761 in 2025
The $761 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $626 · 2022: $499 · 2023: $991 · 2024: $1,153 · 2025: $761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Education: $83.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.77 |
| Education | $83.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $761.07 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $634.56 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Takeda Pharmaceuticals U.S.A., INC. | $519.80 | 2021-2025 | Trintellix |
| Noven Therapeutics, LLC | $387.44 | 2023-2025 | Xelstrym |
| Teva Pharmaceuticals USA, INC. | $317.83 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Vanda Pharmaceuticals INC. | $292.19 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $248.75 | 2022-2025 | Aristada, Lybalvi, Aristada Initio |
| Lundbeck LLC | $211.80 | 2021-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $106.98 | 2023-2024 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $90.25 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $83.93 | 2022-2023 | |
| Corium, LLC | $76.78 | 2024 | Azstarys |
| Idorsia Pharmaceuticals US INC | $55.41 | 2023-2025 | Quviviq, Quviviq |
| E.R. Squibb & Sons, L.L.C. | $40.82 | 2024-2025 | Cobenfy |
| Avanir Pharmaceuticals, INC. | $40.75 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $39.80 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $29.55 | 2021-2022 | |
| Biogen, INC. | $24.08 | 2023 | |
| Almatica Pharma LLC | $19.49 | 2024 | Loreev Xr |
| Collegium Pharmaceutical, INC. | $18.40 | 2025 | Jornay Pm |
| Lilly USA, LLC | $14.93 | 2022 | |
| Tris Pharma INC | $14.57 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheryl List listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.